FDA Approves MAYZENT — Novartis Pharmaceuticals Corporation

On March 26, 2019, the U.S. FDA granted approval to Novartis Pharmaceuticals for Mayzent (siponimod), offering a new oral treatment option for adult patients with active multiple sclerosis. This regulatory milestone was pivotal for Novartis, as the drug became a key driver for the company to expand its multiple sclerosis franchise and capture a substantial share of this lucrative market.